Less than one in 10 individuals that would benefit from GLP-1 drugs such as Wegovy are able to get them, states the World Health Organization as it releases its first advice on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for more widespread and fairer access to this class of drugs.
According to estimates, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"The latest guidance affirms that excess weight is a chronic disease that can be addressed with thorough and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major hurdles to universal availability to the jabs that can assist patients in reducing substantial body mass, says the agency.
Skinny Jab Shortage
Even under the current most favorable outlook, the supply of these medications could only cover approximately 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The advice calls on governments and firms to increase access, through strategies like licensing agreements.
The intellectual property rights on a key compound – the main ingredient of the drug Wegovy – is due to expire in several nations in 2026.
The Way Weight-Loss Jabs Function
These medications mimick a natural hormone to delay gastric emptying, reduce hunger and increase feelings of fullness so people reduce food intake.
Individuals usually see weight reduction in the initial weeks of starting on the weekly injections.
Evidence points to people may regain a significant portion a year later of discontinuing the treatment, when their normal food cravings return.
Being carrying excess weight increases your chance for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.
Obesity impacts people in every country and was responsible for 3.7 million deaths worldwide in 2024, as per the health agency.
